Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 7/20 | 0.65 |
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA9 | Q16790 | 7/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 6/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21017935 | 0.95 | CA1 (0.64) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL13306448 | 0.91 | CA12 (0.63) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL2691444 | 0.85 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16245772 | 0.84 | CA12 (0.73) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30448576 | 0.84 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL22426018 | 0.84 | CA12 (0.60) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL463829 | 0.84 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25718690 | 0.84 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30448898 | 0.82 | CA1 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18199288 | 0.82 | CA12 (0.62) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011005609-A2 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005609-A2 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107248-A1 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY | SLC10A2, KCNN3, KCNN2 | CA12 824/4885CA1 166/4885CA2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.